DanielPeterPetrylakMD

Oncology • New Haven, CT

Genitourinary Oncology, Hematologic Oncology

Yale University Cancer Center

Join to view full profile

Dr. Petrylak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Petrylak's full profile

Already have an account?

Office
35 Park Street Np4
New Haven, CT 06510
Phone+1 203-200-4822

Fax+1 203-785-4043

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1985 - 1988
Case Western Reserve University School of MedicineClass of 1985

Certifications & Licensure

NY State Medical License 1985 - 2026
CT State Medical License 2012 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
America's Top Doctors Castle Connolly, 2006-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
New York Magazine: Top Doctors Castle Connolly, 2005-2009, 2011-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer Start of enrollment: 1996 Jan 01
Completed
Phase 3
Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 1998 Feb 01
Unknown status
Phase 1, Phase 2
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer Start of enrollment: 1998 Aug 01
Unknown status
Phase 1
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 1999 Oct 01
Completed
Phase 3
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Start of enrollment: 2001 Feb 01
Completed
Phase 2
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium Start of enrollment: 2004 Jun 01
Terminated
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer Start of enrollment: 2018 Nov 27
Terminated
Phase 2
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1470 citations
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak
Lancet. 2017-01-07
255 citations
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Ch...
Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot
Journal of Clinical Oncology. 2021-04-30
102 citations
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen
Journal of Clinical Oncology. 2023-01-01

Journal Articles

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Jonathan E Rosenberg, Daniel P Petrylak, The New England Journal of Medicine
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Cora N Sternberg, Jeanny B Aragon-Ching, Daniel P Petrylak, Petros Grivas, The New England Journal of Medicine

Lectures

EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
2019 ASCO Annual Meeting - 6/1/2019
6th Annual Interdisciplinary Prostate Cancer Congress®
Physicians' Education Resource, LLC , Physicians' Education Resource, LLC, New York, New York - 3/16/2013

Press Mentions

Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in Cisplatin-Ineligible Patients with mUC Progressing to Previous Treatment with ICISeptember 16th, 2024
Various Cancer Treatment Drugs Experiencing Nationwide ShortageMay 22nd, 2023
BCG Response in Bladder Cancer Cases Linked to Tumor MicrobiomeMay 16th, 2023
Join now to see all